{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T01:45:47Z","timestamp":1775785547448,"version":"3.50.1"},"reference-count":164,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T00:00:00Z","timestamp":1681689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sj\u00f6gren\u2019s syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and refractory\/intolerance to conventional immunosuppressants demand other options, namely biological drugs, and small molecules. We aimed to define evidence and practice-based guidance for the off-label use of biologics in SLE, APS, and SS. Recommendations were made by an independent expert panel, following a comprehensive literature review and two consensus rounds. The panel included 17 internal medicine experts with recognized practice in autoimmune disease management. The literature review was systematic from 2014 until 2019 and later updated by cross-reference checking and experts\u2019 input until 2021. Preliminary recommendations were drafted by working groups for each disease. A revision meeting with all experts anticipated the consensus meeting held in June 2021. All experts voted (agree, disagree, neither agree nor disagree) during two rounds, and recommendations with at least 75% agreement were approved. A total of 32 final recommendations (20 for SLE treatment, 5 for APS, and 7 for SS) were approved by the experts. These recommendations consider organ involvement, manifestations, severity, and response to previous treatments. In these three autoimmune diseases, most recommendations refer to rituximab, which aligns with the higher number of studies and clinical experience with this biological agent. Belimumab sequential treatment after rituximab may also be used in severe cases of SLE and SS. Second-line therapy with baricitinib, bortezomib, eculizumab, secukinumab, or tocilizumab can be considered in SLE-specific manifestations. These evidence and practice-based recommendations may support treatment decision and, ultimately, improve the outcome of patients living with SLE, APS, or SS.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1117699","type":"journal-article","created":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T11:00:53Z","timestamp":1681729253000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":43,"title":["Biological therapy in systemic lupus erythematosus, antiphospholipid syndrome, and Sj\u00f6gren\u2019s syndrome: evidence- and practice-based guidance"],"prefix":"10.3389","volume":"14","author":[{"given":"Ant\u00f3nio","family":"Marinho","sequence":"first","affiliation":[]},{"given":"Jos\u00e9","family":"Delgado Alves","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Fortuna","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Faria","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Almeida","sequence":"additional","affiliation":[]},{"given":"Gl\u00f3ria","family":"Alves","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Ara\u00fajo Correia","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Campar","sequence":"additional","affiliation":[]},{"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[]},{"given":"Jorge","family":"Crespo","sequence":"additional","affiliation":[]},{"given":"Daniela","family":"Marado","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Matos-Costa","sequence":"additional","affiliation":[]},{"given":"Susana","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Salvador","sequence":"additional","affiliation":[]},{"given":"Lelita","family":"Santos","sequence":"additional","affiliation":[]},{"given":"F\u00e1tima","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Milene","family":"Fernandes","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Vasconcelos","sequence":"additional","affiliation":[]}],"member":"1965","published-online":{"date-parts":[[2023,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv292","article-title":"Prediction and prevention of autoimmune disease in the 21st century: A review and preview","volume":"183","author":"Rose","year":"2016","journal-title":"Am J Epidemiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215089","article-title":"Update of the EULAR recommendations for the management of systemic lupus erythematosus","volume":"78","author":"Fanouriakis","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00472","article-title":"The emerging jamboree of transformative therapies for autoimmune diseases","volume":"11","author":"Carballido","year":"2020","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2020.03.007","article-title":"Challenges, progress, and prospects of developing therapies to treat autoimmune diseases","volume":"181","author":"Fugger","year":"2020","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-11-88","article-title":"Biologic therapy for autoimmune diseases: An update","volume":"11","author":"Rosman","year":"2013","journal-title":"BMC Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.04.011","article-title":"International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus","volume":"16","author":"Kleinmann","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B8","volume-title":"The Oxford 2011 Levels of Evidence","year":"2011"},{"key":"B9","doi-asserted-by":"publisher","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B10","first-page":"476","article-title":"Systemic lupus erythematosus: Pathogenesis and clinical features","volume-title":"EULAR textbook on rheumatic diseases","author":"Bertsias","year":"2012"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.11.034","article-title":"Long-term prognosis and causes of death in systemic lupus erythematosus","volume":"119","author":"Doria","year":"2006","journal-title":"Am J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-Target in systemic lupus erythematosus: Recommendations from an international task force","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8142368","article-title":"Biologics in the treatment of lupus erythematosus: A critical literature review","volume":"2019","author":"Samotij","year":"2019","journal-title":"BioMed Res Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X19874309","article-title":"Biological therapies and their clinical impact in the treatment of systemic lupus erythematosus","volume":"11","author":"Magro","year":"2019","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316655215","article-title":"Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus","volume":"25","author":"Schwarting","year":"2016","journal-title":"Lupus"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200831","article-title":"Effects of belimumab, a b lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials","volume":"71","author":"Manzi","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202865","article-title":"Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials","volume":"73","author":"Strand","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1177\/0961203315625119","article-title":"Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care","volume":"25","author":"Bruce","year":"2016","journal-title":"Lupus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121368","article-title":"Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus","volume":"41","author":"Ginzler","year":"2014","journal-title":"J Rheumatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8675-2","article-title":"Effectiveness, tolerability, and safety of belimumab in patients with refractory SLE: A review of observational clinical-practice-based","volume":"54","author":"Trentin","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212504","article-title":"Lupus low disease activity state (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: Post-hoc analysis of the phase IIb MUSE trial of anifrolumab","volume":"77","author":"Morand","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"B25","article-title":"The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: A decision aid for development of entry criteria for clinical trials","volume":"25","author":"Abrahamowicz","year":"1998","journal-title":"J Rheumatol"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.1002\/1529-0131(199912)42:12<2682::AID-ANR26>3.0.CO;2-6","article-title":"Patterns of disease activity in systemic lupus erythematosus","volume":"42","author":"Barr","year":"1999","journal-title":"Arthritis Rheum"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex395","article-title":"Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: Results from the British Isles Lupus Assessment Group Biologics Register","volume":"57","author":"McCarthy","year":"2018","journal-title":"Rheumatology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313503912","article-title":"Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (Graid)","volume":"22","author":"Witt","year":"2013","journal-title":"Lupus"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/art.27541","article-title":"Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French autoimmunity and rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B32","article-title":"Efficacy and safety of off-label use of rituximab in refractory lupus: Data from the Italian multicentre registry","volume":"33","author":"Iaccarino","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317749047","article-title":"Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus","volume":"27","author":"Iwata","year":"2018","journal-title":"Lupus"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312446627","article-title":"Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The lesimab study","volume":"21","author":"Fernandez-Nebro","year":"2012","journal-title":"Lupus"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/art.40932","article-title":"Rituximab as maintenance treatment for systemic lupus erythematosus: A multicenter observational study of 147 patients","volume":"71","author":"Cassia","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-014-2839-0","article-title":"The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus","volume":"34","author":"Hickman","year":"2015","journal-title":"Clin Rheumatol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1590\/2175-8239-jbn-2018-0254","article-title":"Rituximab use in adult glomerulopathies and its rationale","volume":"42","author":"Santos","year":"2020","journal-title":"J Bras Nefrol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313509295","article-title":"Rituximab in systemic lupus erythematosus: An updated systematic review and meta-analysis","volume":"22","author":"Duxbury","year":"2013","journal-title":"Lupus"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2018.17096","article-title":"Outcomes of rituximab therapy in refractory lupus: A meta-analysis","volume":"5","author":"Alshaiki","year":"2018","journal-title":"Eur J Rheumatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S195113","article-title":"Clinical efficacy and safety of rituximab in lupus nephritis","volume":"13","author":"Zhong","year":"2019","journal-title":"Drug Des Devel Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/imj.13136","article-title":"Single-dose rituximab in refractory lupus nephritis","volume":"46","author":"Kotagiri","year":"2016","journal-title":"Intern Med J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket462","article-title":"Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: A clinical observational study","volume":"53","author":"Moroni","year":"2014","journal-title":"Rheumatology"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e7429","DOI":"10.1097\/MD.0000000000007429","article-title":"Rituximab alone as induction therapy for membranous lupus nephritis: A multicenter retrospective study","volume":"96","author":"Chavarot","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2011.10.009","article-title":"Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts","volume":"11","author":"Diaz-Lagares","year":"2012","journal-title":"Autoimmun Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.8257","article-title":"Effectiveness and safety of common therapeutic drugs for refractory lupus nephritis: A network meta-analysis","volume":"19","author":"Zhou","year":"2020","journal-title":"Exp Ther Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000000273","article-title":"Efficacy and safety of rituximab in systemic lupus erythematosus and Sj\u00f6gren syndrome patients with refractory thrombocytopenia: A retrospective study of 21 cases","volume":"21","author":"Jiang","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24999","article-title":"Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults","volume":"93","author":"Serris","year":"2018","journal-title":"Am J Hematol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1177\/0961203313485489","article-title":"Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: Long-term follow-up and review of the literature","volume":"22","author":"Jovancevic","year":"2013","journal-title":"Lupus"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.reuma.2017.07.023","article-title":"Rituximab in refractory autoimmune hemolytic anemia in systemic lupus erythematosus","volume":"14","author":"Pavo-Blanco","year":"2018","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00163-5","article-title":"Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: A systematic review and meta-analysis","volume":"9","author":"Chao","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1080\/25785826.2019.1696644","article-title":"Successful treatment of a patient with refractory immune thrombocytopenic purpura in systemic lupus erythematosus with rituximab","volume":"42","author":"Abe","year":"2019","journal-title":"Immunol Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0534-3","article-title":"Management of neuropsychiatric systemic lupus erythematosus: Current approaches and future perspectives","volume":"76","author":"Magro-Checa","year":"2016","journal-title":"Drugs"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.06.004","article-title":"Rituximab therapy in refractory neuropsychiatric lupus: Current clinical evidence","volume":"41","author":"Narvaez","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"B55","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/1756-185X.12337","article-title":"Neuro-ophthalmologic manifestations of systemic lupus erythematosus: A systematic review","volume":"17","author":"Man","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-011-1714-5","article-title":"Rituximab in the treatment of severe lupus myelopathy","volume":"30","author":"Ye","year":"2011","journal-title":"Clin Rheumatol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S143768","article-title":"Severe neuropsychiatric systemic lupus erythematosus successfully treated with rituximab: An alternative to standard of care","volume":"9","author":"Chessa","year":"2017","journal-title":"Open Access Rheumatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.4172\/2165-7920.10001033","article-title":"Rituximab as first-line therapy in severe lupus erythematosus with neuropsychiatric and renal involvement: A case-report and review of the literature","volume":"7","author":"Angeletti","year":"2017","journal-title":"J Clin Case Rep"},{"key":"B59","article-title":"Successful sequential therapy with rituximab and belimumab in patients with active systemic lupus erythematosus: A case series","volume":"36","author":"Gualtierotti","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaa117","article-title":"Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results","volume":"36","author":"Kraaij","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"B61","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","article-title":"The net-effect of combining rituximab with belimumab in severe systemic lupus erythematosus","volume":"91","author":"Kraaij","year":"2018","journal-title":"J Autoimmun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu369","article-title":"Belimumab after rituximab as maintenance therapy in lupus nephritis","volume":"53","author":"Kraaij","year":"2014","journal-title":"Rheumatology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2016.01.008","article-title":"Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab","volume":"84","author":"Simonetta","year":"2017","journal-title":"Joint Bone Spine"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/art.41466","article-title":"phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04569-6","article-title":"Primary central nervous system lymphoma in neuropsychiatric systemic lupus erythematosus: Case-based review","volume":"41","author":"Ichikawa","year":"2021","journal-title":"Rheumatol Int"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e032569","DOI":"10.1136\/bmjopen-2019-032569","article-title":"Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT-LUPUS) protocol: A prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial","volume":"9","author":"Jones","year":"2019","journal-title":"BMJ Open"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-025687","article-title":"phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol","volume":"9","author":"Teng","year":"2019","journal-title":"BMJ Open"},{"key":"B68","first-page":"L13","article-title":"Efficacy and safety of subcutaneous belimumab (BEL) and rituximab (RTX) sequential therapy in patients with systemic lupus erythematosus: The phase 3, randomized, placebo-controlled BLISS-BELIEVE study","volume":"73","author":"Aranow","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/cells8080898","article-title":"Pathogenic and therapeutic relevance of Jak\/Stat signaling in systemic lupus erythematosus: Integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent","volume":"8","author":"Alunno","year":"2019","journal-title":"Cells"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: A double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"B71","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S0140-6736(18)32763-6","article-title":"Baricitinib for systemic lupus erythematosus","volume":"393","author":"Yuan","year":"2019","journal-title":"Lancet"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32749-1","article-title":"Baricitinib for systemic lupus erythematosus - authors' reply","volume":"393","author":"Wallace","year":"2019","journal-title":"Lancet"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316686703","article-title":"The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1177\/0961203319896018","article-title":"Efficacy and safety of bortezomib in refractory lupus nephritis: A single-center experience","volume":"29","author":"Segarra","year":"2020","journal-title":"Lupus"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu393","article-title":"Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient","volume":"54","author":"Wang","year":"2015","journal-title":"Rheumatology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket284","article-title":"Efficacy and tolerability of repeated cycles of a once-weekly regimen of bortezomib in lupus","volume":"53","author":"Quartuccio","year":"2014","journal-title":"Rheumatology"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1432331","article-title":"Multicenter double-blind randomized controlled trial to evaluate the effectiveness and safety of bortezomib as a treatment for refractory systemic lupus erythematosus","volume":"28","author":"Ishii","year":"2018","journal-title":"Mod Rheumatol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1177\/0961203317691371","article-title":"Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: Description of two cases","volume":"26","author":"Sjowall","year":"2017","journal-title":"Lupus"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-017-3686-5","article-title":"Expanding the therapeutic options for renal involvement in lupus: Eculizumab, available evidence","volume":"37","author":"Sciascia","year":"2017","journal-title":"Rheumatol Int"},{"key":"B81","article-title":"A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with systemic lupus erythematosus","volume":"50","author":"Furie","year":"2004","journal-title":"Arthritis Rheum"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev307","article-title":"Eculizumab as rescue therapy in severe resistant lupus nephritis","volume":"54","author":"Pickering","year":"2015","journal-title":"Rheumatology"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.0228-17","article-title":"A rare case of lupus nephritis presenting as thrombotic microangiopathy with diffuse pseudotubulization possibly caused by atypical hemolytic uremic syndrome","volume":"57","author":"Ono","year":"2018","journal-title":"Intern Med"},{"key":"B84","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12882-020-01888-5","article-title":"A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy","volume":"21","author":"Wright","year":"2020","journal-title":"BMC Nephrol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2014.12.027","article-title":"Th1\/Th2\/Th17\/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity","volume":"72","author":"Talaat","year":"2015","journal-title":"Cytokine"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318762598","article-title":"A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab","volume":"27","author":"Satoh","year":"2018","journal-title":"Lupus"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314520844","article-title":"Successful application of belimumab in two patients with systemic lupus erythematosus experiencing a flare during tocilizumab treatment","volume":"23","author":"Juptner","year":"2014","journal-title":"Lupus"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1177\/0961203312441046","article-title":"Successful tocilizumab and tacrolimus treatment in a patient with rheumatoid arthritis complicated by systemic lupus erythematosus","volume":"21","author":"Maeshima","year":"2012","journal-title":"Lupus"},{"key":"B90","doi-asserted-by":"publisher","first-page":"bcr2016215423","DOI":"10.1136\/bcr-2016-215423","article-title":"Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous","volume":"2016","author":"Ocampo","year":"2016","journal-title":"BMJ Case Rep"},{"key":"B91","doi-asserted-by":"publisher","first-page":"bcr2012007834","DOI":"10.1136\/bcr-2012-007834","article-title":"Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab","volume":"2012","author":"Kamata","year":"2012","journal-title":"BMJ Case Rep"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kes072","article-title":"Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus","volume":"51","author":"Garcia-Hernandez","year":"2012","journal-title":"Rheumatology"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: The abatacept and cyclophosphamide combination efficacy and safety study","volume":"66","author":"Group","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1002\/art.27601","article-title":"The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211388","article-title":"Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles","volume":"76","author":"Chamberlain","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2023325","article-title":"Targeting CD38 with daratumumab in refractory systemic lupus erythematosus","volume":"383","author":"Ostendorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac393","article-title":"Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus\u2013associated refractory cerebral vasculitis induces immune tolerance","volume":"62","author":"Yalcin Mutlu","year":"2023","journal-title":"Rheumatology"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu429","article-title":"Indications for IVIG in rheumatic diseases","volume":"54","author":"Mulhearn","year":"2015","journal-title":"Rheumatol (Oxford England)"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000000086","article-title":"Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: A systematic review and meta-analysis","volume":"93","author":"Sakthiswary","year":"2014","journal-title":"Medicine"},{"key":"B102","article-title":"Intravenous human immunoglobulin for the treatment of severe longitudinal extensive transverse myelitis associated with systemic lupus erythematous","volume":"43","author":"Duarte","year":"2018","journal-title":"Acta Reumatol Port"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000575","article-title":"Low-dose interleukin-2 therapy for the treatment of systemic lupus erythematosus","volume":"31","author":"Humrich","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/ar2341","article-title":"The role of tumor necrosis factor-alpha in systemic lupus erythematosus","volume":"10","author":"Aringer","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep270","article-title":"Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: Long-term follow-up of 13 patients","volume":"48","author":"Aringer","year":"2009","journal-title":"Rheumatology"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: A randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"17103","DOI":"10.1038\/nrdp.2017.103","article-title":"Antiphospholipid syndrome","volume":"4","author":"Schreiber","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204838","article-title":"Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: A multicentre prospective study of 1000 patients","volume":"74","author":"Cervera","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1177\/0961203320933009","article-title":"Long-term follow-up of antiphospholipid syndrome: Real-life experience from a single center","volume":"29","author":"Serrano","year":"2020","journal-title":"Lupus"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000269","article-title":"Treatment of catastrophic antiphospholipid syndrome","volume":"28","author":"Kazzaz","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B115","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.autrev.2014.03.002","article-title":"14th international congress on antiphospholipid antibodies task force report on catastrophic antiphospholipid syndrome","volume":"13","author":"Cervera","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1177\/0961203310395803","article-title":"Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th international congress on antiphospholipid antibodies","volume":"20","author":"Ruiz-Irastorza","year":"2011","journal-title":"Lupus"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14192","article-title":"Mcmaster RARE-bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"Legault","year":"2018","journal-title":"J Thromb Haemostasis"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.11.009","article-title":"Intravenous immunoglobulins and antiphospholipid syndrome: How, when and why? A review of the literature","volume":"15","author":"Tenti","year":"2016","journal-title":"Autoimmun Rev"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316659548","article-title":"Microangiopathic antiphospholipid antibody-associated syndrome in a pregnant lady","volume":"26","author":"Kew","year":"2017","journal-title":"Lupus"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jri.2016.03.004","article-title":"Apheresis and intravenous immunoglobulins used in addition to conventional therapy to treat high-risk pregnant antiphospholipid antibody syndrome patients. A Prospective Study","volume":"115","author":"Ruffatti","year":"2016","journal-title":"J Reprod Immunol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s11239-014-1061-x","article-title":"Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss","volume":"38","author":"Mar","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"B122","first-page":"299","article-title":"Combination therapy with anticoagulants, corticosteroids and intravenous immunoglobulin for women with severe obstetric antiphospholipid syndrome","volume":"32","author":"Watanabe","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2016.06.086","article-title":"Cutaneous gangrene of the arms and legs after cardiopulmonary resuscitation: A rare presentation of catastrophic antiphospholipid syndrome","volume":"35","author":"Deng","year":"2017","journal-title":"Am J Emergency Med"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1177\/0961203315587960","article-title":"A case of catastrophic antiphospholipid syndrome: First report with advanced cardiac imaging using MRI","volume":"24","author":"Rosenbaum","year":"2015","journal-title":"Lupus"},{"key":"B125","first-page":"206","article-title":"Cyanosis of the foot","volume":"100","author":"Shi","year":"2017","journal-title":"Cutis"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-015-8649-x","article-title":"A therapeutic challenge: Catastrophic anti-phospholipid syndrome with diffuse alveolar haemorrhage","volume":"62","author":"Martis","year":"2015","journal-title":"Immunologic Res"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.5150","article-title":"Atypical subacute recurrence of catastrophic antiphospholipid syndrome in a Japanese female patient","volume":"54","author":"Horikoshi","year":"2015","journal-title":"Intern Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.10.013","article-title":"Antiphospholipid antibodies-associated diffuse alveolar hemorrhage","volume":"44","author":"Yachoui","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.02.002","article-title":"Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: A single-center experience","volume":"46","author":"Wang","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"B131","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11739-016-1596-2","article-title":"Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome","volume":"12","author":"Sciascia","year":"2017","journal-title":"Intern Emerg Med"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318768890","article-title":"Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: The beneficial effect of rituximab treatment","volume":"27","author":"Dioszegi","year":"2018","journal-title":"Lupus"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1282599","article-title":"Severe antiphospholipid antibody syndrome - response to plasmapheresis and rituximab","volume":"28","author":"Gkogkolou","year":"2017","journal-title":"J Dermatol Treat"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"B135","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3390\/biomedicines9020132","article-title":"Immunosuppressive treatment in antiphospholipid syndrome: Is it worth it","volume":"9","author":"Mormile","year":"2021","journal-title":"Biomedicines"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-019-00565-8","article-title":"Eculizumab in refractory catastrophic antiphospholipid syndrome: A case report and systematic review of the literature","volume":"19","author":"Tinti","year":"2019","journal-title":"Clin Exp Med"},{"key":"B137","doi-asserted-by":"publisher","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Sjogren syndrome","volume":"2","author":"Brito-Zeron","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"B138","doi-asserted-by":"publisher","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sj\u00f6gren's syndrome: Beyond the dryness - from pathophysiology to diagnosis and treatment","volume":"14","author":"Both","year":"2017","journal-title":"Int J Med Sci"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22968","article-title":"Treatment guidelines for rheumatologic manifestations of Sj\u00f6gren's syndrome: Use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain","volume":"69","author":"Carsons","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"B140","article-title":"Present and novel biologic drugs in primary Sjogren's syndrome","author":"Fasano","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex166","article-title":"The British Society for Rheumatology guideline for the management of adults with primary Sj\u00f6gren's syndrome","volume":"56","author":"Price","year":"2017","journal-title":"Rheumatology"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-001064","article-title":"Efficacy and safety of topical and systemic medications: A systematic literature review informing the EULAR recommendations for the management of Sjogren's syndrome","volume":"5","author":"Brito-Zeron","year":"2019","journal-title":"RMD Open"},{"key":"B143","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2019-216114","article-title":"EULAR recommendations for the management of Sjogren's syndrome with topical and systemic therapies","volume":"79","author":"Ramos-Casals","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sj\u00f6gren's syndrome with rituximab: A randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/art.40093","article-title":"Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren's syndrome","volume":"69","author":"Bowman","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150749","article-title":"Rituximab effectiveness and safety for treating primary Sj\u00f6gren's syndrome (pSS): Systematic review and meta-analysis","volume":"11","author":"Souza","year":"2016","journal-title":"PloS One"},{"key":"B147","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jbspin.2017.06.004","article-title":"Efficacy and safety of biological DMARDs modulating B cells in primary Sj\u00f6gren's syndrome: Systematic review and meta-analysis","volume":"85","author":"Letaief","year":"2018","journal-title":"Joint Bone Spine"},{"key":"B148","article-title":"Severe, life-threatening phenotype of primary Sj\u00f6gren's syndrome: Clinical characterisation and outcomes in 1580 patients (GEAS-SS registry)","author":"Flores-Chavez","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110077","article-title":"Treatment of mucosa-associated lymphoid tissue lymphoma in Sj\u00f6gren's syndrome: A retrospective clinical study","volume":"38","author":"Pollard","year":"2011","journal-title":"J Rheumatol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: A randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1002\/art.34331","article-title":"A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202293","article-title":"Efficacy of rituximab in systemic manifestations of primary Sj\u00f6gren's syndrome: Results in 78 patients of the autoimmune and rituximab registry","volume":"72","author":"Gottenberg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.057919","article-title":"Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sj\u00f6gren's syndrome","volume":"66","author":"Seror","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"B154","article-title":"Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases","volume":"28","author":"Ramos-Casals","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2020-eurolupus.161","article-title":"P117 rituximab therapy for primary Sj\u00f6gren's syndrome \u2013 a retrospective single-centre study","volume":"7","author":"Figueiras","year":"2020","journal-title":"Lupus Sci Med"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev257","article-title":"Efficacy and safety of belimumab given for 12 months in primary Sj\u00f6gren's syndrome: The BELISS open-label phase II study","volume":"54","author":"De Vita","year":"2015","journal-title":"Rheumatology"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203991","article-title":"Efficacy and safety of belimumab in primary Sj\u00f6gren's syndrome: Results of the BELISS open-label phase II study","volume":"74","author":"Mariette","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-019-04724-w","article-title":"Effectiveness and safety of abatacept for the treatment of patients with primary Sj\u00f6gren's syndrome","volume":"39","author":"Machado","year":"2020","journal-title":"Clin Rheumatol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218599","article-title":"Efficacy and safety of abatacept in active primary Sj\u00f6gren's syndrome: Results of a phase III, randomised, placebo-controlled trial","volume":"80","author":"Baer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30160-2","article-title":"Abatacept treatment for patients with early active primary Sj\u00f6gren's syndrome: A single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study)","volume":"2","author":"van Nimwegen","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/annrheumdis-2020-218272","article-title":"Update on the diagnosis and management of systemic lupus erythematosus","volume":"80","author":"Fanouriakis","year":"2021","journal-title":"Ann Rheumatic Dis"},{"key":"B162","doi-asserted-by":"publisher","first-page":"476","DOI":"10.3390\/vaccines11020476","article-title":"Development of autoantibodies following BNT162b2 mRNA COVID-19 vaccination and their association with disease flares in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and the general population: Results of 1-year prospective follow-up study","volume":"11","author":"Gazitt","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B163","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.autrev.2013.07.007","article-title":"Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: Current views upon safety and immunogenicity","volume":"13","author":"Murdaca","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B164","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.autrev.2018.04.006","article-title":"Recommendations and barriers to vaccination in systemic lupus erythematosus","volume":"17","author":"Garg","year":"2018","journal-title":"Autoimmun Rev"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1117699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,17]],"date-time":"2023-04-17T11:01:05Z","timestamp":1681729265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1117699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,17]]},"references-count":164,"alternative-id":["10.3389\/fimmu.2023.1117699"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1117699","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,17]]},"article-number":"1117699"}}